期刊
BRITISH JOURNAL OF CANCER
卷 113, 期 2, 页码 199-203出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2015.215
关键词
selumetinib; docetaxel; KRAS; mutation; codon; non-small-cell lung cancer
类别
资金
- AstraZeneca
Background: Selumetinib (AZD6244, ARRY-142886) + docetaxel increases median overall survival (OS) and significantly improves progression-free survival (PFS) and objective response rate (ORR) compared with docetaxel alone in patients with KRAS mutant, stage IIIB/IV non-small-cell lung cancer (NSCLC; NCT00890825). Methods: Retrospective analysis of OS, PFS, ORR and change in tumour size at week 6 for different sub-populations of KRAS codon mutations. Results: In patients receiving selumetinib+docetaxel and harbouring KRAS G12C or G12V mutations there were trends towards greater improvement in OS, PFS and ORR compared with other KRAS mutations. Conclusion: Different KRAS mutations in NSCLC may influence selumetinib/docetaxel sensitivity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据